1. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers

2. Introduction

3. The Role of the Pulmonologist

4. Lung Cancer Biopsies

5. "Reflex" or Automatic Testing

6. DNA Mutational Analysis

7. Should We Reflex Test Early Stage Lung Cancer?

8. Testing Guidelines: CAP/IASLC/AMP

9. NCCN Testing Guidelines

10. PD-L1 IHC

11. Squamous Cell Carcinoma: NCCN Guidelines

12. Appropriate Techniques For Getting Tissue For Genetic and IHC Testing

13. Communication Is Key!

14. Benefits of EBUS

15. Survival Improves When Eligible Patients Receive Targeted Therapy

16. First-Line TKI Therapy in EGFR-Mutated NSCLC Randomized Phase 3 Trials

17. Pulmonary Toxicity

18. Ongoing Role of Pulmonologist

19. Additional Testing at Progression

20. T790M+ Patients Have Improved PFS With Osimertinib Instead of Chemotherapy

21. Blood vs Tissue Testing

22. Concluding Remarks

23. Abbreviations

24. Abbreviations (cont)

25. Abbreviations (cont)